¿··¿¥³¥í¥Ê¡Ã¿··¿¥³¥í¥Ê¥ï¥¯¥Á¥ó²òÀ⡡³Êó
¥¡¼¥ï¡¼¥É
¿··¿¥³¥í¥Ê¡¡¥ï¥¯¥Á¥ó
°ÊÁ°¡Ö¥³¥í¥Ê¥¦¥¤¥ë¥¹¥ï¥¯¥Á¥ó²òÀâ¡×¤ò·ÇºÜ¤·¤¿¤È¤³¤í¡¢ÍÍ¡¹¤Ê°Õ¸«¤¬ÆϤ¤Þ¤·¤¿¡£
¤½¤ÎÃæ¤Ç¤â
¡Ö¥ï¥¯¥Á¥ó¤òÂǤĤȡ¢°äÅÁ»Ò¤¬ÊѤï¤ë¡×
¤È¤¤¤¦¾ðÊó¤Ç¡¢¥ï¥¯¥Á¥ó¤Ë²ûµ¿Åª¤Ê°Õ¸«¤¬¤¢¤ê¤Þ¤·¤¿¤Î¤Ç̾¸Å²°À¸³è¥¯¥é¥Ö¤È¤·¤Æ¤Î¸«²ò¤ò
·ÇºÜ¤·¤Þ¤¹¡£
¡Ö¥¢¥Ç¥Î¥¦¥¤¥ë¥¹·¿¥ï¥¯¥Á¥ó¡Ê¥¢¥¹¥È¥é¥¼¥Í¥«¡¢¥¸¥ç¥ó¥½¥ó¡õ¥¸¥ç¥ó¥½¥ó¾¡Ë¡¢mRNA·¿¥ï¥¯¥Á¥ó¡Ê¥Õ¥¡¥¤¥¶¡¼¡¢¥â¥Ç¥ë¥Ê¡Ë
¶¦¤Ë¡¢°äÅÁ»Ò¤ËÁȤ߹þ¤Þ¤ì¤ë²ÄǽÀ¤Ï¤¢¤ê¤Þ¤¹¡£¡×
¤¿¤À¤½¤ì¤ò¡Ö¥ï¥¯¥Á¥ó¤òÂǤĤȰäÅÁ»Ò¤¬¤«¤ï¤ë¡£¡×
¤È¤¿¤À¶²ÉÝ¿´¤òÀú¤ë¤³¤È¤Ëµ¿Ìä¤ò´¶¤¸¤Þ¤¹¡£
¤½¤â¤½¤â¡¢¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹¤Ë´¶À÷¤¹¤ë¤À¤±¤Ç¡¢¥³¥í¥Ê¤Î°äÅÁ»Ò¤¬°ìÉôÁȤ߹þ¤Þ¤ì¤Æ¤¤¤Þ¤¹¡£
Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured
human cells and can be expressed in patient-derived tissues
¥µ¡¼¥º¥³¥í¥Ê¥¦¥¤¥ë¥¹¡¼£²¤ÎRNA¤Ï¡¢µÕž¼Ì¤µ¤ì¡ÊDNA¤ËÊѲ½¤·¡Ë¡¢¥Ò¥È¡¢¥²¥Î¥à¤Ë
ÁÞÆþ¤µ¤ì¤Æ¡¢È¯¸½¤¹¤ë¡Ê¥¿¥ó¥Ñ¥¯¼Á¤òÀ¸À®¤¹¤ë¡Ë
PNAS¡¡May 25.2021 118(21)
¿©¤Ùʪ¤Ç¤â°äÅÁ»Ò¤ËÆþ¤ê¹þ¤à¾ì¹ç¤¬¤¢¤ê¤Þ¤¹¡£
Foreign (M13)DNA ingested by mice reach peripheral leukocytes.spleen and
liver via tha intestinal wall mucosa and can be covallently linked to mouse DNA
¥Þ¥¦¥¹¤Ë·ë¹çŪ¤ËÀݼ褵¤»¤¿¡Ö¤è¤½Êª¡×¤ÎDNA¤Ï¡¢Ä²¤Ø¤Ç´Ëì¤òÄ̤äÆ
Ëö¾¿Çò·ìµå¡¢¤Ò¡¡¢´Î¡¤ËÆþ¤ë¡£¥Þ¥¦¥¹¤ÎDNA¤È·ë¹ç¤·¤Æ¤¤¤ë¤Î¤Ç
¡Ê¥Þ¥¦¥¹¤ÎDNA¤ËÁÞÆþ¤µ¤ì¤Æ¤¤¤ë¡Ë
PNAS.94¡Ê1997¡Ë961-966
°äÅÁ»Ò¤ËÁȤ߹þ¤Þ¤ì¤ëȯÀ¸²ÄǽÀ¤È¡¢¤½¤Î±Æ¶Á¤Ë¤Ä¤¤¤Æ¹Í¤¨¤Þ¤¹¡£
¡¡¡¡¡¡¡¡¥ï¥¯¥Á¥ó¤¬°äÅÁ»Ò¤ØÁȤ߹þ¤Þ¤ì¤ë»ÅÁȤߤȤ½¤ÎȯÀ¸²ÄǽÀ¡¡¡¡¡¡
¥¢¥Ç¥Î¥¦¥¤¥ë¥¹DNA·¿¥ï¥¯¥Á¥ó¤Ë¤Ï¡¢½É¼ç.DNA¤Ø¤ÎÁȤ߹þ¤ß¤ÎÍýÏÀŪ²ÄǽÀ¤¬¤¢¤ë¤¬¡¢
mRNA·¿¥ï¥¯¥Á¥ó¤Ë¤Ï¤½¤Î²ÄǽÀ¤Ï¤Û¤È¤ó¤É̵¤¤¡£
- mRNA¤¬ÁȤ߹þ¤Þ¤ì¤ë¤¿¤á¤Ë¤Ï
£í£Ò£Î£Á→°ìËܺ¿£Ä£Î£Á→ÆóËܺ¿£Ä£Î£Á→ÁȤ߹þ¤ß
¤½¤ì¤¾¤ì¤Ë¹ÚÁǤ䳫»Ï°ø»Ò¤Ê¤É¤¬É¬Í×
- ȯÀ¸²ÄǽÀ¤¬Ä㤤Íýͳ
mRNA¤Ï¡¢ºÙ˦¼Á¤Ë¤¢¤ê¡¢³Ë¡Ê£Ä£Î£Á¤¬¤¢¤ë¡Ë¤Ë¤Ï°Ü¹Ô¤·¤Ê¤¤
¥ï¥¯¥Á¥ó¤Ë´Þ¤Þ¤ì¤Æ¤¤¤ë£í£Ò£Î£Á¤Ï¡¢Á᤯ʬ²ò¤¹¤ë¡£
½É¼ç¤Î£Ò£Î£Á¤¬ÂçÎ̤˸ºß¤¹¤ëÃæ¤Ç¡¢¥ï¥¯¥Á¥ó¤Î£í£Ò£Î£Á¤¬Í¥ÀèŪ¤Ë°ìËܺ¿£Ä£Î£Á¤ËÊÑ´¹¤¹¤ë²ÄǽÀ¤ÏÄ㤤¡£
Devoelopment of mRNA vaccines:scientific and regulatory issues
mRNA¥ï¥¯¥Á¥ó¤Î³«È¯¡¢²Ê³ØŪ¡¢µÚ¤Ó¹ÔÀ¯Åª²ÝÂê¡£
Vaccines¡¡2021.9.81¡¡WHO.FDA¡Ê¥¢¥á¥ê¥«¿©ÉÊ°åÌôÉʶɡË
⤷¡¢¥¢¥Ç¥Î¥¦¥¤¥ë¥¹DNA·¿¥ï¥¯¥Á¥ó¤Ï°äÅÁ»Ò¤¬ÁȤ߹þ¤Þ¤ì¤¿¤ê¡¢»×¤ï¤ÌÌȱÖÈ¿±þ¤¬µ¯¤¤ë²ÄǽÀ¤¬¤¢¤ê¤Þ¤¹¡£
Adenovirus -Antibody complexes coutributed to lethal systemic inflammation
in a Gene Therapy Trial.
¥¢¥Ç¥Î¥¦¥£¥ë¥¹¤òÍѤ¤¤¿°äÅÁ»Ò¼£ÎŤǥ¢¥Ç¥Î¥¦¥£¥ë¥¹°ì¹³ÂΡ¡Ê£¹çÂΤ¬À¸¤¸¡¢
Á´¿È¤Î±ê¾É¤¬À¸¤¸¡¢´µ¼Ô¤¬»àË´¤·¤¿¡£
Molecular Therapy 28.3 March 2020.
¡¡¡¡¡¡¡¡¥ï¥¯¥Á¥óÀܼï¤Ë¤è¤ëÉûºîÍѤˤĤ¤¤ÆÆüËܤϤۤȤó¤ÉÄ´ºº¤µ¤ì¤Æ¤¤¤Ê¤¤¡¡¡¡¡¡
¸üÀ¸Ï«Æ¯¾Ê¤Îȯɽ¡Ê¥Õ¥¡¥¤¥¶¡¼¡¢¥ï¥¯¥Á¥ó¡Ë
ÎáÏÂ3ǯ2·î17Æü¤«¤éÎáÏÂ3ǯ5·î30Æü¤Þ¤Ç¤ËÊó¹ð¤µ¤ì¤¿»àË´»öÎã¤Ï·×139·ï¤È¤Ê¤Ã¤¿¡£¤½¤ÎÆâ¡¢¾ðÊóÉÔÂÅù¤Ë¤è¤ê°ø²Ì´Ø·¸¤¬É¾²Á¤Ç¤¤Ê¤¤¤â¤Î139·ï¡¡¡¡
¡áÆüËܤϤۤȤó¤ÉÄ´ºº¤µ¤ì¤Æ¤¤¤Ê¤¤
¥¤¥¹¥é¥¨¥ëÊÝ·ò¾Ê¤ÎÊó¹ð¡ÊMinistry of Health¡Ë
2020ǯ12·î¡Á2021ǯ5·î¤Þ¤Ç¤Ëµ¯¤¤¿¿´¶Ú±ê¤ÎÊó¹ð
504Ëü9424¿Í¤ÎÀܼï¼Ô¤ÎÆâ¡¢2²óÌܤÎÀܼï¸å30Æü°ÊÆâ¤Ë121¿Í¤¬¿´¶Ú±ê¤òµ¯¤³¤·¤¿¡£
¡Ê16ºÍ¡Á19ºÍ¤Î¼ã¤¤ÃËÀ¤Ë¿¤¤¡Ë
¤Û¤È¤ó¤É¤ÎÎã¤ÇÆþ±¡¤Ï4Æü¤Þ¤Ç¡£95%¤Ï¥Þ¥¤¥ë¥É¤Ê¾ÉÎã
·ëÏÀ¡¡
16ºÍ¡Á30ºÍ¤Þ¤Ç¤Î¼ã¤¤ÃËÀ¤Î¿´¶Ú±ê¤È2²óÌܤΥ說¥Á¥óÀܼï¤Ë´Ø·¸¤¬¤¢¤ë²ÄǽÀ¤¬¤¢¤ë
¥¤¥¹¥é¥¨¥ëÀ¯ÉܤÏ37¤Î¥Á¡¼¥à¤òºî¤Ã¤ÆÄ´ºº¤·¤Æ¤¤¤ë¡£
¥¤¥¹¥é¥¨¥ë¤Ï¥Õ¥¡¥¤¥¶¡¼¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£
¥¢¥á¥ê¥«¤Ç¤âƱÍͤο´¶Ú±ê¤¬Â¿¤¯¤Ê¤Ã¤Æ¤ª¤ê¡¢CDC¤ÎÀìÌç²È²ñµÄ¤¬³«ºÅ¤µ¤ì¤ë¤½¤¦¤Ç¤¹¡£¡Ê6·î18Æü¡Ë
Ç¥ÉؤؤαƶÁ¤ÎÄ´ºº
Immunogenicity of £ÃOVID-19 mRNA vaccines in pregnant and lactating women
JAMA May 13,2021
mRNA¥ï¥¯¥Á¥ó¡Ê¥Õ¥¡¥¤¥¶¡¼¡¢¥â¥Ç¥ë¥Ê¡Ë¤ò2020ǯ12·î¤«¤é2021ǯ3·î¤Ë¤«¤±¤Æ¼õ¤±¤¿ÉØ¿Í103¿Í¡Ê18ºÍ¡Á45ºÍ¡Ë¡£¤½¤ÎÆ⡢ǥ¿±Ã椬30¿Í¡¢Ó®ÆýÃ椬16¿Í¡¢¤½¤ì°Ê³°57¿Í
¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¤¬¤¢¤ê¡¢¥ï¥¯¥Á¥ó¤ò¼õ¤±¤Æ¤¤¤Ê¤¤Ç¥ÉØ22¿Í¡¢Ç¥¿±¤·¤Æ¤¤¤Ê¤¤¿Í6¿Í¡¡¡¡¡¡
·ëÏÀ¡¡
mRNA¥ï¥¯¥Á¥ó¤ÏÇ¥Éؤµ¤ó¤ÎÌȱÖÈ¿±þ¤òµ¯¤³¤·¡¢À¸¤¸¤¿¹³ÂΤÏÂÛ»ù¤Î¤µ¤¤ÂÓ·ìµÚ¤ÓÊìÆý¤Ë°Ü¹Ô¤·¤¿¡£¥¤¥¹¥é¥¨¥ë¤ÎBeth Deaconess °åÎÅ¥»¥ó¥¿¡¼¤Î¸¦µæ¤Ç¤¹¡£
Ç¥Éؤµ¤ó¡¢Ó®ÆýÃæ¤È¤â¤ËmRNA¥ï¥¯¥Á¥ó¡Ê¥Õ¥¡¥¤¥¶¡¼¡¢¥â¥Ç¥ë¥Ê¡Ë¤ÏÌȱÖÈ¿±þ¤òµ¯¤³¤·¡¢¹³ÂΤ¬ºî¤é¤ì¤¿¡£
Severe Acute Respiratory Syudrome Coronavirus2 (SARS-CoV-2)Vaccination in pregnancy
06sterics and Gynecology May 11,2021
¥Î¡¼¥¹¥¦¥¨¥¹¥¿¥óÂç³Ø¡¡¥¢¥á¥ê¥«
¥³¥í¥Ê¥¦¥¤¥ë¥¹2¤ËÂФ¹¤ë¥ï¥¯¥Á¥ó¤Ï¡¢¶ÛµÞ»ÈÍѤϵö²Ä¤µ¤ì¤¿¤¬Ç¥¿±Ãæ¤Î½÷À¤Ï¥ê¥¹¥¯¤¬¹â¤¤¤¿¤á¡¢Î×¾²¸¦µæ¤«¤éÇ¥Éؤϳ°¤µ¤ì¤¿¡£
º£¤Þ¤Ç¤Î¸¦µæ¤Ç¡¢ÂÛÈפ˥ꥹ¥¯¤¬¤¢¤êÆÀ¤ë¤Î¤Ç¡¢Â¿¤¯¤ÎÇ¥Éؤ¬¥ï¥¯¥Á¥ó¤ò»È¤Ã¤Æ¤«¤é½é¤á¤Æ¤ï¤«¤ëµ©¤Ê¾ã³²¤¬¤¢¤ë²ÄǽÀ¤¬¤¢¤ë¡£
æÍîËìÆ°Ì®¾É
mRNA¥ï¥¯¥Á¥ó¤Ï¡¢¥Þ¥¦¥¹¤Î¼Â¸³¤Ç¤Ï¡¢¥È¡¼¥ëÍͥꥻ¥×¥¿¡¼3¤Î³èÀ²½¤Ë¤è¤Ã¤ÆÌȱÖÈ¿±þ¤òµ¯¤³¤¹¤Î¤Ç¡¢Ã¦ÍîËìÆ°Ì®¾É¡¢À®Ä¹Á˳²¡¢Ì¤½Ï»ù¡¢ÂÛ»ù¤Î»àË´¤Ê¤É¤Î²ÄǽÀ¤¬¤¢¤ë¡£¡Ê¥Þ¥¦¥¹¤Î¼Â¸³¡Ë
ÊýË¡
84¿Í¤Î¥ï¥¯¥Á¥óÀܼ路¤¿Ç¥Éءʽлº¤Ï2021ǯ1·î¡Á4·î¡Ë¡¢¥ï¥¯¥Á¥ó¤òÀܼ路¤Æ¤¤¤Ê¤¤ÂоȤÎÇ¥ÉØ116¿Í¡Ê½Ð»º¤Ï2020ǯ4·î¡Á2021ǯ4·î¡Ë¤òÈæ¤Ù¤¿¡£
·ë²Ì
¥ï¥¯¥Á¥óÀܼï¼Ô¤ÎÊý¤¬¡¢¤è¤ê»ºÆ»¤«¤é»º¤Þ¤ì¤¿¡£¹³ÂΤò»ý¤Ã¤Æ¤¤¤¿¡£
°ìÊý¡¢Âоȼԡʥ說¥Á¥óÈóÀܼï¡Ë¤Ï¹³ÂΤ¬Ìµ¤«¤Ã¤¿¡£
¥ï¥¯¥Á¥óÀܼï¼Ô¤ÎÂÛÈפÏæÍîËìÆ°Ì®¾É¤Ê¤É¤Î¾ã³²¤¬ÂоȤËÈæ¤Ù¤Æ¿¤¯¤Ê¤«¤Ã¤¿¡£
°Ëß·¤Î´¶ÁÛ
¥¢¥Ç¥Î¥¦¥£¥ë¥¹·¿¥ï¥¯¥Á¥ó¤Ï¡¢¼ÂºÝ¤Ë·ìÀò¤¬À¸¤¸¤Æ¤¤¤ëÍͤˡ¢°äÅÁ»Ò¤¬ÁȤ߹þ¤Þ¤ì¤¿¤ê¡¢
»×¤ï¤ÌÌȱÖÈ¿±þ¤¬¡¢¾¯¤Ê¤¤¤Ê¤¬¤éµ¯¤¤ë²ÄǽÀ¤¬¤¢¤ê¤½¤¦¤Ç¤¹¡£
mRNA·¿¤â½É¼çDNA¤ËÁȤ߹þ¤Þ¤ì¤ë²ÄǽÀ¤Ï¡¢¤Û¤È¤ó¤É̵¤¤¤È¡¢
WHO¡¢FDA¤ÏÏÀʸ¤ò½Ð¤·¤Æ¤¤¤Þ¤¹¤¬¡¢ºÇ¶á¤ÎÏÀʸ¤Ç¥Ý¥ê¥á¥é¡¼¥¼¡¡¥»¡¼¥¿¡¼¤¬
£Ò£Î£Á¤ò£Ä£Î£Á¤ËÊÑ´¹¤¹¤ë¡ÊScience¡¡Advances 11.June 2021¡Ë
¤È¤¤¤¦ÏÀʸ¤â¤¢¤ê¤Þ¤¹¡£
¥Í¥º¥ß¤Î¼Â¸³¤Ç¤¹¤¬¡¢¸ý¤«¤éÀݼ褵¤ì¤¿³°ÍèDNA¤¬¥Í¥º¥ß¤ÎDNA¤Ë¾¯¿ô¤Ê¤¬¤éÁȤ߹þ¤Þ¤ì¤Æ¤¤¤ë¡£¤È¤¤¤¦ÏÀʸ¤â¤¢¤ê¤Þ¤¹¡£
¤½¤â¤½¤â¡¢¿··¿¥³¥í¥Ê¤Ë´¶À÷¤¹¤ë¤À¤±¤Ç¥³¥í¥Ê¤Î°äÅÁ»Ò¤¬°ìÉôʬÁȤ߹þ¤Þ¤ì¤Æ¤¤¤Þ¤¹¡£
¡Ê´µ¼Ô¤Î10¡Á20¡ó¡Ë
²Ê³ØŪ¤Ê¸¡¾Ú¤Ï¡¢ÏÀʸ¤È¤¤¤¦·Á¤Ç¸øÊ¿¤ËµÄÏÀ¤µ¤ì¤ëɬÍפ¬¤¢¤ê¤Þ¤¹¡£ÆüËܤθüÀ¸Ï«Æ¯¾Ê¤ÎÄ´ºº¤·¤Ê¤¤ÂμÁ¤¬¹ṉ̃¤ÎÉÔ¿®¤ò¾·¤¤¤Æ¤ë¤È»×¤¤¤Þ¤¹¡£ÏÀʸ¤È¤¤¤¦»ö¼Â¤Ë´ð¤Å¤¤¤Æ¥ï¥¯¥Á¥ó¤Î°ÂÁ´À¤òɾ²Á¤·¤Þ¤·¤ç¤¦¡£
º£²óÄ´¤Ù¤¿ÏÀʸ¤Ç¤Ï¡¢Ç¥Éؤµ¤ó¤Ë¤Ï¤¢¤ë°ìÄêÄøÅ٤ΰÂÁ´À¡Ê¥ê¥¹¥¯¤¬¥¼¥í¤Ç¤Ï¤Ê¤¤¡Ë¤¬¤¢¤ë¤¬¡¢¼ã¤¤ÃËÀ¤Ë¤Ï¿´¶Ú±ê¤Î¥ê¥¹¥¯¤¬¤¢¤ê¤½¤¦¤À¤È¤¤¤¦¤â¤Î¤Ç¤¹¡£¤½¤ì¤Ë¤·¤Æ¤â¡¢¸üÀ¸Ï«Æ¯¾Ê¤¬¥ï¥¯¥Á¥óÀܼï¸å¤Î»àË´¤Ë¤Ä¤¤¤Æ¡¢¤¤Á¤ó¤ÈÄ´ºº¤·¤Ê¤¤¤Î¤ÏÏÀ³°¤Ç¡¢¹ṉ̃¤¬ÉÔ¿®¤ò»ý¤Ä¤Î¤â¤·¤ç¤¦¤¬¤Ê¤¤¤Ê¤È¤â»×¤¤¤Þ¤¹¡£
¤·¤«¤·¡¢¤À¤«¤é¤È¤¤¤Ã¤Æ¡¢»ö¼Â¤Ë´ð¤Å¤«¤Ê¤¤¡Ö¥¬¥»¥Í¥¿¡×¤¬Â¿¤¤¤Î¤âº¤¤ê¤â¤Î¤Ç¤¹¡£ÏÀʸ¤Ë´ð¤Å¤«¤Ê¤¤¤Î¤Ê¤é²¿¤Ç¤â¸À¤¨¤Æ¤·¤Þ¤¦¤·¡¢»ö¼Â¤½¤¦¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£Àµ¤·¤¤»ö¼Â¤ò¤Ä¤«¤ß¤Þ¤·¤ç¤¦¡£¡Ê°ËÂô¡Ë
º£¤ÏÏÀʸ¤ò¸µ¤ËÎäÀŤ˥說¥Á¥óÀܼï¤Ë¤Ä¤¤¤Æ¸Ä¿Í¤¬È½ÃǤǤ¤ë¤È¤è¤¤¤È»×¤¤
¤³¤Îµ»ö¤ò½ñ¤¤¤Æ¤¤¤Þ¤¹¡£
http://1.nagoyaseikatsuclub.com/?eid=341
http://1.nagoyaseikatsuclub.com/?eid=319
http://1.nagoyaseikatsuclub.com/?eid=318
http://1.nagoyaseikatsuclub.com/?eid=317
http://1.nagoyaseikatsuclub.com/?eid=304
http://1.nagoyaseikatsuclub.com/?eid=303
http://1.nagoyaseikatsuclub.com/?eid=301
http://1.nagoyaseikatsuclub.com/?eid=300